Corrigendum to ‘A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19’

Corrigendum to ‘A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19’

Bibliographic Details
Main Authors:	Oliver J McElvaney, Brian D Hobbs, Dandi Qiao, Oisín F McElvaney, Matthew Moll, Natalie L McEvoy, Jennifer Clarke, Eoin O'Connor, Sean Walsh, Michael H Cho, Gerard F Curley, Noel G McElvaney
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396420304928

Similar Items

A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19
by: Oliver J McElvaney, et al.
Published: (2020-11-01)

Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients.
by: Francesco Palmas, et al.
Published: (2021-01-01)

Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm
by: Noel G. McElvaney
Published: (2015-03-01)

Prone positioning improves oxygenation and lung recruitment in patients with SARS-CoV-2 acute respiratory distress syndrome; a single centre cohort study of 20 consecutive patients
by: Jennifer Clarke, et al.
Published: (2021-01-01)

Weaving a Personal Web: Using online technologies to create customized, connected, and dynamic learning environments
by: Jessica McElvaney, et al.
Published: (2010-05-01)

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
by: Karen McQuillan, et al.
Published: (2020-07-01)

Altered Serum Alpha1-Antitrypsin Protease Inhibition before and after Clinical Hematopoietic Stem Cell Transplantation: Association with Risk for Non-Relapse Mortality
by: Ido Brami, et al.
Published: (2023-12-01)

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets
by: Vega-Carrascal I, et al.
Published: (2012-08-01)

Perceiving threat in others: The role of body morphology.
by: Terence J McElvaney, et al.
Published: (2021-01-01)

MicroRNAs in inflammatory lung disease - master regulators or target practice?
by: Greene Catherine M, et al.
Published: (2010-10-01)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
by: Alfawaz Bader, et al.
Published: (2013-01-01)

Adolescents’ experiences of psychotherapy following child sexual abuse
by: Rosaleen McElvaney, et al.
Published: (2023-07-01)

The efficacy of internet-delivered treatment for generalized anxiety disorder: A systematic review and meta-analysis
by: Derek Richards, et al.
Published: (2015-09-01)

Editorial: Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
by: Carla Maria Pedrosa Ribeiro, et al.
Published: (2021-11-01)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
by: Chotirmall, Sanjay Haresh, et al.
Published: (2015)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
by: Dunlea DM, et al.
Published: (2018-03-01)

Preventing depression: Qualitatively examining the benefits of depression-focused iCBT for participants who do not meet clinical thresholds
by: C. Earley, et al.
Published: (2017-09-01)

Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
by: Oisin F. McElvaney, et al.
Published: (2022-03-01)

Impaired Airway Epithelial Barrier Integrity in Response to Stenotrophomonas maltophilia Proteases, Novel Insights Using Cystic Fibrosis Bronchial Epithelial Cell Secretomics
by: Kevin Molloy, et al.
Published: (2020-02-01)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
by: Chapman KR, et al.
Published: (2018-01-01)

Respiratory epithelial cells require Toll-like receptor 4 for induction of Human β-defensin 2 by Lipopolysaccharide
by: McElvaney Noel, et al.
Published: (2005-10-01)

Characterisation of the Major Extracellular Proteases of <em>Stenotrophomonas maltophilia</em> and Their Effects on Pulmonary Antiproteases
by: Kevin Molloy, et al.
Published: (2019-06-01)

Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation
by: Shuren Ma, et al.
Published: (2019-06-01)

Altered Degranulation and pH of Neutrophil Phagosomes Impacts Antimicrobial Efficiency in Cystic Fibrosis
by: Elaine Hayes, et al.
Published: (2020-12-01)

A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial
by: Natalie L. McEvoy, et al.
Published: (2021-04-01)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
by: O'Shea O, et al.
Published: (2023-06-01)

miR-224-5p and miR-545-5p Levels Relate to Exacerbations and Lung Function in a Pilot Study of X-Linked MicroRNA Expression in Cystic Fibrosis Monocytes
by: Paul J. McKiernan, et al.
Published: (2021-11-01)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
by: Padraig Hawkins, et al.
Published: (2021-08-01)

Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
by: Robin Caird, et al.
Published: (2022-06-01)

Emotion-focused therapy as a transdiagnostic treatment for depression, anxiety and related disorders: Protocol for an initial feasibility randomised control trial [version 1; peer review: 3 approved]
by: Ladislav Timulak, et al.
Published: (2020-02-01)

Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke
by: Dorscheid Delbert R, et al.
Published: (2007-11-01)

Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
by: Michelle M. White, et al.
Published: (2017-09-01)

Antimicrobial proteins and polypeptides in pulmonary innate defence
by: Taggart Clifford C, et al.
Published: (2006-02-01)

Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
by: Bergin DA, et al.
Published: (2013-01-01)

“How many times did I not want to live a life because of him”: the complex connections between child sexual abuse, disclosure, and self-injurious thoughts and behaviors
by: Delphine Collin-Vézina, et al.
Published: (2021-01-01)

Determining rates of smoking cessation advice delivered during hospitalisation and smoking cessation rates 3 months post discharge: a two-hospital survey
by: Lisa Mellon, et al.
Published: (2016-01-01)

The BLT1 inhibitory function of α-1 antitrypsin augmentation therapy disrupts leukotriene B4 neutrophil signaling
by: O’Dwyer, C, et al.
Published: (2015)

Innate immunity in cystic fibrosis lung disease.
by: Hartl, D, et al.
Published: (2012)

Ataluren, a new therapeutic for alpha-1 antitrypsin deficient individuals with nonsense mutations
by: Reeves, E, et al.
Published: (2018)

Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care
by: Alessandro N. Franciosi, et al.
Published: (2022-12-01)